Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Eligible age
19+ yrs
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).
Sponsor: SCRI Development Innovations, LLC
You may qualify if…
- ✓ 1. Age \>18 years with no upper age limit.
- ✓ 2. Newly diagnosed multiple myeloma with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and response assessment must be available.
- ✓ 3. Eligible for ASCT according to institutional policy as evaluated by investigator.
- ✓ 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (Appendix A).
- ✓ 5. Prior induction therapy including one PI, lenalidomide, and an anti-CD38 mAb for 16-24 weeks, obtaining at least a partial response (PR).
- ✓ 6. Measurable disease meeting at least 1 of the following criteria (at the time of diagnosis):
- ✓ a. Serum monoclonal (M) protein ≥1.0 g/dl (≥0.5 g/dl if IgA, IgD, IgE or IgM MM).
- ✓ b. ≥200 mg of M protein/24h in the urine. c. Difference between affected and unaffected free light chain ≥10 mg/dL with abnormal kappa to lambda ratio.
You may not qualify if…
- ✕ 1. Diagnosis of primary light chain amyloidosis, POEMS, Waldenstrom's macroglobulinemia, plasma cell leukemia, or central nervous system (CNS) involvement by MM.
- ✕ 2. Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients (refer to the elranatamab Investigator's Brochure \[IB\] and appropriate package inserts).
- ✕ 3. Prior or concurrent exposure to any of the following:
- ✕ c. Any anti-BCMA therapy. d. Epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 21 days or ≥5 half-lives, whichever is less.
- ✕ e. Investigational vaccine within 4 weeks. f. Live, attenuated vaccine within 4 weeks before randomization. g. Radiotherapy within 14 days. h. Gene-modified adoptive cell therapy (e.g., CAR modified T cells, NK cells). i. Cytotoxic therapy within 14 days.
- ✕ 4. Minimum washout period for prior therapy:
- ✕ 1. PI therapy - 14 days.
- ✕ 2. IMiD agent therapy -14 days.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06974786 · last updated 2026-06-04